

March 18, 2020

SUBSTANTIALLY EQUIVALENT

Philip Morris USA Inc.
Attention: Rebecca A. Rivas, Senior Director, Regulatory Submissions
Altria Client Services LLC
601 East Jackson Street
Richmond, Virginia 23219

FDA Submission Tracking Numbers (STNs): Multiple STNs, see Appendix A

Dear Ms. Rivas:

We completed our review of your SE Reports¹ and determined that the new tobacco products are substantially equivalent to the corresponding predicate tobacco products listed in Appendix A² and are in compliance with the requirements of the FD&C Act. Under the provisions of section 910 and 905(j) of the FD&C Act, you may introduce or deliver for introduction into interstate commerce the new tobacco products subject of this letter.

Our finding does <u>not</u> mean we "approved" the new products specified in Appendix A; therefore, you may not promote or in any way represent the new tobacco products specified in Appendix A, or the labeling, as being "approved" by FDA (see Section 301(tt) of the FD&C Act).

For information on how to fulfill the provisions of section 910(a)(4) of the FD&C Act, refer to Appendix B.

In accordance with 40 CFR 1506.6, we will make your Environmental Assessment (EA) publicly available.

All regulated tobacco products, including the tobacco products specified in Appendix A, are subject to the requirements of the FD&C Act and its implementing regulations. It is your responsibility to ensure the tobacco products specified in Appendix A complies with all applicable statutory and regulatory requirements. FDA will monitor your compliance with all applicable statutes and regulations.

found that those differences do not cause the new tobacco products to raise different questions of public health, and thus the new tobacco products are also substantially equivalent to the grandfathered products in SE0014886, SE0014279, SE0004306, SE0004305, SE0014888, and SE0014890.

_

¹ Substantially Equivalent (SE) Reports submitted under section 905(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) ² In addition to comparing the new tobacco products to the predicate tobacco products named by the applicant, FDA also compared the new tobacco products in these SE Reports to the grandfathered tobacco products in SE0014886, SE0014279, SE0004306, SE0004305, SE0014888, and SE0014890, respectively. Although the new products have different characteristics than the grandfathered tobacco products in SE0014886, SE0014279, SE0004306, SE0004305, SE0014888, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014888, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014888, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014888, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014888, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014889, and SE0014890, FDA found that these differences do not source the new tobacco products in Se014890, FDA found that these differences do not source the new tobacco products in Se014890, FDA found that these differences do not source the new tobacco products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found that the selection of the second products in Se014890, FDA found the second products in Se014890, FDA found the second products in Se014890, FDA found the second p

If you have any questions, please contact Pin Zhang, Ph.D., Regulatory Health Project Manager, at (240) 402 – 0997 or Pin.Zhang@fda.hhs.gov.

Sincerely,

Digitally signed by Matthew R. Holman -S Date: 2020.03.18 13:17:59 -04'00'

Matthew R. Holman, Ph.D. Director Office of Science Center for Tobacco Products

Enclosures:

Appendix A – New and Corresponding Predicate Tobacco Products Subject of This Letter Appendix B – Health Information Summary

Appendix A

New and Corresponding Predicate Tobacco Products Subject of This Letter

Common Attributes of 3E Ne	Common Attributes of SE Reports			
Date of Submission: De	ecember 20, 2019			
Date of Receipt: De	ate of Receipt: December 20, 2019			
Product Manufacturer: Philip Morris USA Inc.				
Product Category: Cig				
Product Sub-Category: Combusted, Filtered				
New	/ Tobacco Product	Predicate Tobacco Product		
SEOO	015617: Marlboro Black Special	SE0014886: Marlboro Black Special		
Blen	d 100's Box ^{3, 4}	Blend 100's Box 3, 4		
Package Type: Har	d Pack	Hard Pack		
Package Quantity: 20 (Cigarettes	20 Cigarettes		
Characterizing Flavor: Nor		None		
Eligibility Status: N/A	A	Previously Found SE		
Length: 99.0	0 millimeters (mm)	99.0 mm		
Diameter: 7.89	9 mm	7.89 mm		
Ventilation: 15.0	0%	15.0%		
Additional Property: Tipp	ping Paper 1	Tipping Paper 1		
New	Tobacco Product	Predicate Tobacco Product		
SE00	015618: Marlboro Black Special	SE0014279: Marlboro Soft Pack ^{3, 4}		
Blen	d Box ^{3, 4}			
Package Type: Har	d Pack	Soft Pack		
Package Quantity: 20 0	Cigarettes	20 Cigarettes		
Characterizing Flavor: Nor	ne	None		
Eligibility Status: N/A	4	Previously Found SE		
Length: 84.0	0 mm	84.0 mm		
Diameter: 7.89	9 mm	7.89 mm		
Ventilation: 15.0	0%	15.0%		
Additional Property: Nor	ne	None		
New	/ Tobacco Product	Predicate Tobacco Product		
SE00	015621: Marlboro Eighty-Threes	SE0004306: Marlboro Eighty-Threes		
Box ³	, 4	Box ^{3, 4}		
Package Type: Har	d Pack	Hard Pack		
Package Quantity: 20 0	Cigarettes	20 Cigarettes		
Characterizing Flavor: Nor	ne	None		
Eligibility Status: N/A	A	Previously Found SE		
Length: 83.0	0 mm	83.0 mm		
Diameter: 7.89	9 mm	7.89 mm		
Ventilation: 15.0	0%	15.0%		
Additional Property: Nor	ne	None		

³ Brand/sub-brand or other commercial name used in commercial distribution.

⁴ The applicant submitted the circumference which allowed for a calculation of diameter.

	New Tobacco Product	Predicate Tobacco Product
	SE0015622: Marlboro Soft Pack ^{3, 4}	SE0004305: Marlboro Soft Pack ^{3, 4}
Package Type:	Soft Pack	Soft Pack
Package Quantity:	20 Cigarettes	20 Cigarettes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Previously Found SE
Length:	83.0 mm	83.0 mm
Diameter:	7.89 mm	7.89 mm
Ventilation:	15.0%	15.0%
Additional Property:	None	None
	New Tobacco Product	Predicate Tobacco Product
	SE0015633: Marlboro Black Special	SE0014888: Marlboro Black Special
	Blend 100's Box ^{3, 4}	Blend 100's Box ^{3, 4}
Package Type:	Hard Pack	Hard Pack
Package Quantity:	20 Cigarettes	20 Cigarettes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Previously Found SE
Length:	99.0 mm	99.0 mm
Diameter:	7.89 mm	7.89 mm
Ventilation:	15.0%	15.0%
Additional Property:	Tipping Paper 2	Tipping Paper 2
	New Tobacco Product	Predicate Tobacco Product
	SE0015634: Marlboro Black Special	SE0014890: Marlboro Black Special
	Blend 100's Box ^{3, 4}	Blend 100's Box ^{3, 4}
Package Type:	Hard Pack	Hard Pack
Package Quantity:	20 Cigarettes	20 Cigarettes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Previously Found SE
Length:	99.0 mm	99.0 mm
Diameter:	7.89 mm	7.89 mm
Ventilation:	15.0%	15.0%
Additional Property:	Tipping Paper 3	Tipping Paper 3

Appendix B

Health Information Summary

Your SE Reports did not provide a summary of any health information related to the new tobacco products, required by section 910(a)(4) of the FD&C Act; however, your SE Reports stated that such information will be available upon request to any person. Consistent with the requirements of section 910(a)(4), you may wish to consider providing the following when information is requested:

- A. A copy of your final SE Reports upon which the Substantially Equivalent order was based, redacted only to the extent necessary to exclude patient identifiers and trade secret and confidential commercial information as defined in 21 CFR 20.61 and 20.63.
- B. Any research or data you have in your possession or otherwise know of specifically regarding the adverse health effects of the new tobacco products, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

Alternatively, you may provide the following when information is requested:

Description of the new tobacco products

Description of the predicate tobacco products

List of all differences in characteristics between the new and predicate tobacco products Summary of the evidence and scientific rationale concerning why the differences in characteristics do not raise different questions of public health

Any research or data you have in your possession or otherwise know of regarding the adverse health effects of the new tobacco product, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

There may be other accurate, complete, and not false or misleading ways to satisfy the requirements of section 910(a)(4) not included above. If you wish to discuss other ways to meet the requirements of section 910(a)(4), submit a meeting request to us.